Rettie, Allan E.

THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”

Paine, M. F., Hart, H. L., Ludington, S. S., Haining, R. L., Rettie, A. E., & Zeldin, D. C. (2006) · Drug Metabolism and Disposition

Pharmacogenetics and Drug MetabolismDrug Transport and Resistance Mechanisms

Cited by 870

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose

Cooper, G. M., Johnson, J. A., Langaee, T. Y., Feng, H., Stanaway, I. B., Schwarz, U. I., Ritchie, M. D., Stein, C. M., Roden, D. M., Smith, J. D., et al. (2008) · Blood

Pharmacogenetics and Drug MetabolismGenetic Associations and Epidemiology

Cited by 481

Human Hepatic Flavin-Containing Monooxygenases 1 (FMO1) and 3 (FMO3) Developmental Expression

Koukouritaki, S. B., Simpson, P., Yeung, C. K., Rettie, A. E., & Hines, R. N. (2002) · Pediatric Research

Pharmacogenetics and Drug MetabolismDrug-Induced Hepatotoxicity and Protection

Cited by 245

Oxidation of Acetaminophen to Its Toxic Quinone Imine and Nontoxic Catechol Metabolites by Baculovirus-Expressed and Purified Human Cytochromes P450 2E1 and 2A6

Chen, W., Koenigs, L. L., Thompson, S. J., Peter, R. M., Rettie, A. E., Trager, W. F., & Nelson, S. D. (1998) · Chemical Research in Toxicology

Drug-Induced Hepatotoxicity and ProtectionPharmacogenetics and Drug Metabolism

Cited by 226

Association of FMO3 Variants and Trimethylamine N-Oxide Concentration, Disease Progression, and Mortality in CKD Patients

Robinson-Cohen, C., Newitt, R., Shen, D. D., Rettie, A. E., Kestenbaum, B. R., Himmelfarb, J., & Yeung, C. K. (2016) · PLOS ONE

Pharmacogenetics and Drug MetabolismChronic Kidney Disease and Diabetes

Cited by 63